Share This Page

Support & Insight for the Autumn of Life

BioGen Alzheimer’s Drug BIB-037 Inspires Optimism

VIDEO & ARTICLE:

BIIB-037 binds to and eliminates Alzheimer’s plaque. The experimental drug did a surprisingly good job of improving cognition in recent trials. It is now being rushed into advanced Phase III clinical trials. Watch NBC discuss the breakthrough. Read the key facts.


Biogen Idec Inc. reported encouraging interim results from an early-stage study on its anti-amyloid beta antibody, BIIB037. Biogen is evaluating BIIB037 for the treatment of Alzheimer’s disease. The data was presented at the Deutsche Bank BioFEST conference.

Continued below video…

According to reports from various sources, interim results from the phase Ib study, which was conducted on 194 Alzheimer patients demonstrated both dose- and time-dependent reductions in beta-amyloid levels in the brain. Moreover, a statistically significant improvement in cognition was observed after 54 weeks of treatment. However, there were some side effects called amyloid related imaging abnormalities (ARIA).

Biogen intends to move the candidate into advanced phase III clinical trials based on the promising results.

According to the Alzheimer’s Association, Alzheimer’s is the most common form of dementia, affecting nearly 5 million people in the U.S. aged 65 years and above. The successful development of therapies for the treatment of Alzheimer’s disease is challenging and several companies including Eli Lilly, Johnson & Johnson, as well as Pfizer, have faced setbacks.

Notwithstanding, experts feel that with BIIB-037, "there should be a greater degree of optimism than we have seen before."


SOURCE:

Email me when people comment
Notify of
guest

2 Comments
Inline Feedbacks
View all comments
rongablue
rongablue
December 9, 2014 4:14 pm

What were the side effects please?

AlzWeekly.com
AlzWeekly.com
Reply to  rongablue
December 10, 2014 8:51 am

According to Alzforum.org:

Thus far, 21 study participants had a total of 43 side effects, Sevigny reported. They included headache, diarrhea, and dizziness. Most were mild, some were moderate, none severe, and none became worse with higher doses, Sevigny said.

See the article at:
http://www.alzforum.org/news/conference-coverage/safe-4-grams-no-aria-high-dose-human-av-antibody

B. Berger

B. Berger

This site was inspired by my Mom’s autoimmune dementia.

It is a place where we separate out the wheat from the chaffe, the important articles & videos from each week’s river of news. With a new post on Alzheimer’s or dementia appearing on the internet every 7 minutes, the site’s focus on the best information has been a help to many over the past 15 years. Thanks to our many subscribers for your supportive feedback.

The site is dedicated to all those preserving the dignity of the community of people living with dementia.

Peter Berger, Editor

Share this page To

Related:

Share to Facebook
Twitter
LinkedIn

This site was inspired by my Mom’s autoimmune dementia.

It is a place where we separate out the wheat from the chaffe, the important articles & videos from each week’s river of news. With a new post on Alzheimer’s or dementia appearing on the internet every 7 minutes, the site’s focus on the best information has been a help to many over the past 15 years. Thanks to our many subscribers for your supportive feedback.

The site is dedicated to all those preserving the dignity of the community of people living with dementia.

Peter Berger, Editor

Visit Alzheimer's Weekly On

2
0
Would love your thoughts, please comment.x
()
x
News, Treatments, Care Tips

Subscribe To The Alzheimer's & Dementia Weekly Newsletter

videos & articles on Research & Prevention
News to Get at the Truth

Subscribe To Our Weekly Newsletter

×